Jan 7 (Reuters) - ALLOY THERAPEUTICS:
* ALLOY THERAPEUTICS: ANNOUNCES A TARGET SPECIFIC COLLABORATION & LICENSE AGREEMENT FOR USE OF ANTICLASTIC ANTISENSE PLATFORM WITH SANOFI
* ALLOY THERAPEUTICS: SANOFI TO PROVIDE ALLOY WITH UPFRONT LICENSE FEES & NEAR-TERM PRECLINICAL MILESTONE PAYMENTS UP TO $27.5 MILLION
* ALLOY THERAPEUTICS: UNDER AGREEMENT, ALLOY ALSO ELIGIBLE TO RECEIVE DISCOVERY, DEVELOPMENT, AND COMMERCIAL MILESTONE PAYMENTS OF OVER $400 MILLION
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.